Form 8-K - Current report:
SEC Accession No. 0001641172-25-014224
Filing Date
2025-06-09
Accepted
2025-06-09 06:13:10
Documents
15
Period of Report
2025-06-09
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 39175
2 EX-99.1 ex99-1.htm EX-99.1 15668
3 GRAPHIC form8-k_001.jpg GRAPHIC 5705
  Complete submission text file 0001641172-25-014224.txt   240348

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE lpcn-20250609.xsd EX-101.SCH 3015
5 XBRL LABEL FILE lpcn-20250609_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE lpcn-20250609_pre.xml EX-101.PRE 22359
18 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3681
Mailing Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108
Business Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108 801 994 7383
Lipocine Inc. (Filer) CIK: 0001535955 (see all company filings)

EIN.: 990370688 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36357 | Film No.: 251032773
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)